Works matching AU Watanabe, Junichiro


Results: 54
    1
    2
    3
    4
    5
    6
    7
    8

    High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician's choice—in the EMBRACE study.

    Published in:
    Breast Cancer (13406868), 2020, v. 27, n. 4, p. 706, doi. 10.1007/s12282-020-01067-2
    By:
    • Miyoshi, Yasuo;
    • Yoshimura, Yuta;
    • Saito, Kenichi;
    • Muramoto, Kenzo;
    • Sugawara, Michiko;
    • Alexis, Karenza;
    • Nomoto, Kenichi;
    • Nakamura, Seigo;
    • Saeki, Toshiaki;
    • Watanabe, Junichiro;
    • Perez-Garcia, Jose Manuel;
    • Cortes, Javier
    Publication type:
    Article
    9

    Metastatic breast carcinoma of the abdominal wall muscle: a case report.

    Published in:
    Breast Cancer (13406868), 2015, v. 22, n. 2, p. 206, doi. 10.1007/s12282-012-0352-3
    By:
    • Ogiya, Akiko;
    • Takahashi, Kaoru;
    • Sato, Mutsumi;
    • Kubo, Yoshiko;
    • Nishikawa, Noriko;
    • Kikutani, Mariko;
    • Tadokoro, Yukiko;
    • Tanaka, Kumiko;
    • Uematsu, Takayoshi;
    • Watanabe, Junichiro;
    • Kasami, Masako;
    • Yamasaki, Seiji
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16

    Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.

    Published in:
    2018
    By:
    • Yokota, Tomoya;
    • Bendell, Johanna;
    • LoRusso, Patricia;
    • Tsushima, Takahiro;
    • Desai, Ved;
    • Kenmotsu, Hirotsugu;
    • Watanabe, Junichiro;
    • Ono, Akira;
    • Murugesan, Bhavani;
    • Silva, Joseph;
    • Naito, Tateaki;
    • Greenberg, Jonathan;
    • Kumar, Prasanna;
    • Wang, Yibin;
    • Jikoh, Takahiro;
    • Shiga, Ryota;
    • Hyman, David M.;
    • Ho, Alan Loh;
    • Spriggs, David R.;
    • Schwartz, Gary K.
    Publication type:
    journal article
    17
    18
    19

    Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

    Published in:
    Cancer Science, 2017, v. 108, n. 5, p. 987, doi. 10.1111/cas.13221
    By:
    • Tamura, Kenji;
    • Inoue, Kenichi;
    • Masuda, Norikazu;
    • Takao, Shintaro;
    • Kashiwaba, Masahiro;
    • Tokuda, Yutaka;
    • Iwata, Hiroji;
    • Yamamoto, Naohito;
    • Aogi, Kenjiro;
    • Saeki, Toshiaki;
    • Nakayama, Takahiro;
    • Sato, Nobuaki;
    • Toyama, Tatsuya;
    • Ishida, Takanori;
    • Arioka, Hitoshi;
    • Saito, Mitsue;
    • Ohno, Shinji;
    • Yamauchi, Hideko;
    • Yamada, Kimito;
    • Watanabe, Junichiro
    Publication type:
    Article
    20
    21
    22
    23
    24
    25

    Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 3, p. 407, doi. 10.1007/s00280-012-1924-9
    By:
    • Murakami, Haruyasu;
    • Doi, Toshihiko;
    • Yamamoto, Nobuyuki;
    • Watanabe, Junichiro;
    • Boku, Narikazu;
    • Fuse, Nozomu;
    • Yoshino, Takayuki;
    • Ohtsu, Atsushi;
    • Otani, Satoru;
    • Shibayama, Kazuhiro;
    • Takubo, Takatoshi;
    • Loh, Elwyn
    Publication type:
    Article
    26
    27
    28
    29
    30
    31

    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

    Published in:
    Breast Cancer Research & Treatment, 2018, v. 167, n. 1, p. 81, doi. 10.1007/s10549-017-4489-9
    By:
    • Niikura, Naoki;
    • Shimomura, Akihiko;
    • Fukatsu, Yumi;
    • Sawaki, Masataka;
    • Ogiya, Rin;
    • Yasojima, Hiroyuki;
    • Fujisawa, Tomomi;
    • Yamamoto, Mitsugu;
    • Tsuneizumi, Michiko;
    • Kitani, Akira;
    • Watanabe, Junichiro;
    • Matsui, Akira;
    • Takahashi, Yuko;
    • Takashima, Seiki;
    • Shien, Tadatoshi;
    • Tamura, Kenji;
    • Saji, Shigehira;
    • Masuda, Norikazu;
    • Tokuda, Yutaka;
    • Iwata, Hhiroji
    Publication type:
    Article
    32
    33

    Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.

    Published in:
    Breast Cancer Research & Treatment, 2017, v. 162, n. 3, p. 501, doi. 10.1007/s10549-017-4138-3
    By:
    • Iwata, Hiroji;
    • Masuda, Norikazu;
    • Yamamoto, Daigo;
    • Sagara, Yoshiaki;
    • Sato, Nobuaki;
    • Yamamoto, Yutaka;
    • Saito, Mitsue;
    • Fujita, Takashi;
    • Oura, Shoji;
    • Watanabe, Junichiro;
    • Tsukabe, Masami;
    • Horiguchi, Kazumi;
    • Hattori, Satoshi;
    • Matsuura, Yoshimasa;
    • Kuroi, Katsumasa
    Publication type:
    Article
    34
    35

    Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.

    Published in:
    Breast Cancer Research & Treatment, 2017, v. 161, n. 3, p. 473, doi. 10.1007/s10549-016-4075-6
    By:
    • Yamamoto, Daigo;
    • Sato, Nobuaki;
    • Rai, Yoshiaki;
    • Yamamoto, Yutaka;
    • Saito, Mitsue;
    • Iwata, Hiroji;
    • Masuda, Norikazu;
    • Oura, Shoji;
    • Watanabe, Junichiro;
    • Hattori, Satoshi;
    • Matsuura, Yoshimasa;
    • Kuroi, Katsumasa
    Publication type:
    Article
    36
    37

    Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.

    Published in:
    Investigational New Drugs, 2017, v. 35, n. 6, p. 791, doi. 10.1007/s10637-017-0486-4
    By:
    • Watanabe, Junichiro;
    • Ito, Yoshinori;
    • Ohsumi, Shozo;
    • Mizutani, Mitsuhiro;
    • Tashiro, Hideya;
    • Sakurai, Kenichi;
    • Takahashi, Masato;
    • Saito, Tsuyoshi;
    • Tsurutani, Junji;
    • Mukai, Hirofumi;
    • Yoshinami, Tetsuhiro;
    • Takao, Shintaro;
    • Yamamoto, Yasuhisa;
    • Matsuoka, Toshiyuki;
    • Iwase, Hirotaka;
    • Iwata, Hiroji;
    • Nakamura, Seigo;
    • Saeki, Toshiaki
    Publication type:
    Article
    38
    39

    Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2012, v. 30, n. 6, p. 2352, doi. 10.1007/s10637-011-9789-z
    By:
    • Takahashi, Toshiaki;
    • Boku, Narikazu;
    • Murakami, Haruyasu;
    • Naito, Tateaki;
    • Tsuya, Asuka;
    • Nakamura, Yukiko;
    • Ono, Akira;
    • Machida, Nozomu;
    • Yamazaki, Kentaro;
    • Watanabe, Junichiro;
    • Ruiz-Garcia, Ana;
    • Imai, Keiji;
    • Ohki, Emiko;
    • Yamamoto, Nobuyuki
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    48
    49
    50